07:00 , Aug 13, 2007 |  BioCentury  |  Product Development

Cephalon's pain sales

Cephalon's pain sales Actiq fentanyl sales grew at an average annual rate of 83% from the time Cephalon acquired the drug via its purchase of Anesta in 2000 until it faced generic competition starting last...
07:00 , Aug 13, 2007 |  BioCentury  |  Product Development

Faster followers in pain

When Cephalon Inc. bought Anesta Corp. in 2000 for $444 million in stock, the main driver of the deal was Actiq transmucosal fentanyl for breakthrough cancer pain. The acquisition didn't take long to pay dividends,...
07:00 , Jun 20, 2005 |  BioCentury  |  Strategy

Stepwise into cancer

Cephalon Inc. has had a toehold in the cancer space since its 2000 acquisition of Anesta Corp. gave it Actiq oral transmucosal fentanyl , which is marketed for breakthrough cancer pain. The company also has...
07:00 , May 23, 2005 |  BioCentury  |  Strategy

Buying the unique selling proposition

Although Cephalon Inc. 's planned acquisition of Salmedix Inc. for $160 million in cash plus $40 million in royalties is the company's first acquisition of a pure play cancer company, the deal fits CEPH's modus...
07:00 , Sep 6, 2004 |  BioCentury  |  Strategy

Asset accumulation

A few months ago, BioCentury spilled a lot of ink to deconstruct the NRDO model of no-research, development only companies being formed to scavenge for products or technologies that can be commercialized quickly and offer...
07:00 , Aug 23, 2004 |  BioCentury  |  Product Development

The growing fentanyl crowd

Cephalon Corp. has done a nice job of turning Actiq oral transmucosal fentanyl for breakthrough cancer pain into a moneymaker. When CEPH acquired Anesta Corp. in 2000, Actiq sales were $15 million a year. This...
07:00 , Aug 16, 2004 |  BioCentury  |  Finance

Ebb & Flow

Investors reacted badly to Monday's post-market news that Barr (BRL) will receive a license from Cephalon (CEPH) to sell generic oral transmucosal fentanyl starting Feb. 3, 2007. CEPH was off $4.86 (10%) to $43 on...
07:00 , Sep 22, 2003 |  BioCentury  |  Product Development

Actiq sales

Actiq sales Reformulated pain drugs can enjoy significant sales growth. Cephalon (CEPH) gained the rights to breakthrough cancer pain drug Actiq transmucosal fentanyl in October 2000 when it acquired Anesta in a $336 million stock...
07:00 , Sep 22, 2003 |  BioCentury  |  Product Development

Painfully slow

Pain is an underserved market because the use of opioid agonists to treat moderate to severe pain is limited by common side effects like grogginess and constipation, the development of tolerance and dependence, and the...
07:00 , Jul 7, 2003 |  BioCentury  |  Finance

Helping push open a window

Helping push open a window Historically, the public equity market has been busy before the IPO window opened, as shown by selected U.S. financing events between the bottoms of the last two biotech bear markets...